Innovative approaches for cocaine pharmacotherapy using fMRI: The case of varenicline - Pharmacotheraphy for cocaine addiction: varenicline

Academisch Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•1. male, aged 18-60 years;
•2. current DSM-IV diagnosis of cocaine dependence, but recently detoxified and abstinent;
•3. able to provide written informed consent and to comply with all study procedures.

•1. Currently dependent on any substance other than cocaine or nicotine;
•2. History of depression that could be defined as even a single episode or recurrent episodes of depression, or depression necessitating hospitalization, or history of suicide attempt;
•3. Severe neurological or psychiatric disorders (e.g., psychosis, bipolar illness, dementia, or any diseases that require psychotropic medications);
•4. Serious medical illnesses;
•5. Known hypersensitivity or allergy to varenicline, or receiving chronic therapy with medication that could interact adversely with one of the medications under study, within 30 days prior to randomization;
•6. Drugs known to influence binding to DA2 receptors, including neuroleptics, and methylphenidate;
•7. Received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment;
•8. Clinically significant abnormal laboratory values, as measured by the treatment centre;
•9. Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication.

发起方